Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Denali Therapeutics Inc (NASDAQ: DNLI) closed at $13.91 up 0.94% from its previous closing price of $13.78. In other words, the price has increased by $0.94 from its previous closing price. On the day, 0.75 million shares were traded.
Ratios:
For a deeper understanding of Denali Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.56 and its Current Ratio is at 9.56. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 06 ’25 when Ho Carole sold 12,255 shares for $20.22 per share. The transaction valued at 247,796 led to the insider holds 178,580 shares of the business.
Ho Carole sold 2,907 shares of DNLI for $60,495 on Jan 07 ’25. The Chief Medical Officer now owns 175,673 shares after completing the transaction at $20.81 per share. On Jan 06 ’25, another insider, Schuth Alexander O., who serves as the COFO and Secretary of the company, sold 12,255 shares for $20.22 each. As a result, the insider received 247,796 and left with 247,215 shares of the company.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is -2.34%, while the 200-Day Moving Average is calculated to be -36.04%.
Shares Statistics:
A total of 145.25M shares are outstanding, with a floating share count of 125.78M. Insiders hold about 13.42% of the company’s shares, while institutions hold 89.92% stake in the company.
Earnings Estimates
Investors are keenly observing as 14.0 analysts analyze and rate the current performance of Denali Therapeutics Inc (DNLI) in the stock market.The consensus estimate for the next quarter is -$0.76, with high estimates of -$0.64 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.35 and -$3.61 for the fiscal current year, implying an average EPS of -$3.05. EPS for the following year is -$2.79, with 14.0 analysts recommending between -$1.98 and -$3.68.
Revenue Estimates
Based on 17 analysts’ estimates, the company’s revenue will be $109.34M in the next fiscal year. The high estimate is $284.12M and the low estimate is $9.56M.
